+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn

+ Translate
+ Recently Requested

Effect of timing of growth hormone administration on plasma growth-hormone-binding activity, insulin-like growth factor-I and growth in children with a subnormal spontaneous secretion of growth hormone



Effect of timing of growth hormone administration on plasma growth-hormone-binding activity, insulin-like growth factor-I and growth in children with a subnormal spontaneous secretion of growth hormone



Hormone Research 39(5-6): 188-191



Since normal pulsatile growth-hormone (GH) secretion displays a major and consistent surge during sleep, we studied the effect of timing of GH supplementation on plasma GH-binding protein activity (GH-BP), insulin-like growth factor-I (IGF-I) and growth. 34 prepubertal subjects (28 boys, 6 girls) aged 8-11 years, of short stature ( lt 2 SD for age), with a GH response to provocative test gt 10 mu-g/l and a subnormal 24-hour GH secretion ( lt 3 mu-g/l), were randomly allocated to receive Bio-Tropin (recombinant GH, Bio-Technology, Israel) 0.81 IU/kg/week in 3 equally divided doses. GH was administered either at 8.00-1 0.00 h (M group), 14.00-16.00 h (AN group) or 19.00-2 1.00 h (NT group). Height velocity, IGF-I and GHBP were determined prior to and after 6 and 12 months on GH therapy in the three groups. There was no significant difference between the three groups in the growth response, IGF-I and GH-BP increase, all of which increased significantly during GH therapy. Although GH levels after the injection decline to preinjection levels after 10 h, the changes induced by GH therapy, as reflected in IGF-I and GH-BP, last in the circulation long enough to prevent fluctuations in its action. The similarity of IGF-I and of GH-BP levels in the three treatment groups might explain the similar growth effects of the 3 protocols.

(PDF emailed within 1 workday: $29.90)

Accession: 008550279

Download citation: RISBibTeXText

PMID: 8314201



Related references

Growth hormone/insulin-like growth factor-1 response to acute and chronic growth hormone-releasing peptide-2, growth hormone-releasing hormone 1-44NH2 and in combination in older men and women with decreased growth hormone secretion. Endocrine 14(1): 79-86, 2001

Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children. Clinical Pharmacology and Therapeutics 70(1): 91-98, 2001

Plasma growth hormone-binding protein activity, insulin-like growth factor I, and its binding protein levels in patients with Turner's syndrome: effect of short- and long-term recombinant human growth hormone administration. Pediatric Research 37(1): 106-111, 1995

Adult growth hormone deficiency treatment with a combination of growth hormone and insulin-like growth factor-1 resulting in elevated sustainable insulin-like growth factor-1 and insulin-like growth factor binding protein 3 plasma levels: a case report. Journal of Medical Case Reports 4: 305, 2010

Daily low-dose administration of growth hormone secretagogue stimulates pulsatile growth hormone secretion and elevates plasma insulin-like growth factor-1 levels in pigs. Endocrine 16(3): 195-199, 2002

Oral dehydroepiandrosterone supplementation modulates spontaneous and growth hormone-releasing hormone-induced growth hormone and insulin-like growth factor-1 secretion in early and late postmenopausal women. Fertility & Sterility 76(2): 241-248, 2001

Effect of growth hormone releasing hormone on plasma growth hormone in relation to magnitude and duration of growth hormone deficiency in 26 children and adults with isolated growth hormone deficiency or multiple pituitary hormone deficiencies evidence for hypothalamic growth hormone releasing hormone deficiency. Journal of Clinical Endocrinology & Metabolism 58(6): 1043-1049, 1984

Effects of repetitive administration of growth hormone-releasing hormone on growth hormone secretion, insulin-like growth factor I, and bone metabolism in postmenopausal women. Acta Endocrinologica 120(1): 121-128, 1989

Effect of human pancreatic growth hormone releasing factor 44 on plasma growth hormone secretion in children with various status of growth hormone secretion. Acta Endocrinologica Supplementum 103(256): 70, 1983

Growth response to growth hormone (GH) treatment relates to serum insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in short children with various GH secretion capacities. Swedish Study Group for Growth Hormone Treatment. Journal of Clinical Endocrinology and Metabolism 82(9): 2889-2898, 1997

Intranasal administration of growth hormone-releasing hormone -amide in children with growth hormone deficiency Effects on growth hormone secretion and growth. Acta Paediatrica Supplement 0(388): 23-26, 1993

Secretion of growth hormone following administration of growth hormone releasing factor in children with constitutional short stature or idiopathic growth hormone deficiency. Monatsschrift Kinderheilkunde 135(2): 114-115, 1987

Outpatient assessment of residual growth hormone secretion in treated acromegaly with overnight urinary growth hormone excretion, random serum growth hormone and insulin like growth factor-1. Clinical Endocrinology 49(5): 647-652, 1999

Outpatient assessment of residual growth hormone secretion in treated acromegaly with overnight urinary growth hormone excretion, random serum growth hormone and insulin like growth factor-1. Clinical Endocrinology 49(5): 647-652, 1998

Outpatient assessment of residual growth hormone secretion in treated acromegaly with overnight urinary growth hormone excretion, random serum growth hormone and insulin life growth factor-1. Clinical Endocrinology 49(5): 647-652, 1998